Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting
Recruiting
Observational Study
Heart Failure
Coronary Arterial Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 72 (estimated)
- Sponsor
- Pyatigorsk City Clinical Hospital Number 1 · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg/day on right ventricular-pulmonary artery coupling measured by the TAPSE/PASP ratio in 72 patients with left ventricular ejection fraction \<50% after off-pump coronary artery bypass grafting (OPCAB). The primary outcome is the change in TAPSE/PASP ratio from 1 month after surgery (before dapagliflozin)…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 18 years
* Elective isolated off-pump coronary artery bypass grafting (OPCAB)
* Left ventricular ejection fraction (LVEF) \< 50% documented on pre-operative echocardiography
* Written informed consent
Exclusion Criteria:
* Concomitant valve surgery
* Emergency or urgen…
Contacts